Hsbc Holdings PLC Tcr2 Therapeutics Inc. Transaction History

Hsbc Holdings PLC

  • $160 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.83 - $1.44 $1,281 - $2,223
-1,544 Reduced 8.21%
17,257 $17,000
Q3 2022

Nov 14, 2022
SELL
$1.86 - $3.75 $544 - $1,098
-293 Reduced 1.53%
18,801 $33,000
Q4 2021

Feb 11, 2022
BUY
$4.58 - $8.34 $87,450 - $159,243
19,094 New
19,094 $88,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email